Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) released its quarterly earnings results on Friday. The company reported ($3.29) EPS for the quarter, missing analysts' consensus estimates of ($3.20) by ($0.09), Zacks reports. Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%.
Praxis Precision Medicines Price Performance
NASDAQ:PRAX traded down $1.28 on Monday, hitting $38.96. 431,998 shares of the company's stock were exchanged, compared to its average volume of 385,784. The firm has a 50-day moving average price of $36.68 and a 200-day moving average price of $61.98. The company has a market cap of $793.58 million, a P/E ratio of -3.78 and a beta of 2.65. Praxis Precision Medicines has a 52 week low of $26.70 and a 52 week high of $91.83.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on PRAX. Needham & Company LLC restated a "buy" rating and set a $80.00 target price on shares of Praxis Precision Medicines in a research note on Monday. Wedbush increased their price target on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the company an "underperform" rating in a report on Monday. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Praxis Precision Medicines in a report on Tuesday, February 11th. They set a "buy" rating and a $111.00 price objective on the stock. Robert W. Baird decreased their target price on Praxis Precision Medicines from $117.00 to $73.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $105.00 price target on shares of Praxis Precision Medicines in a report on Thursday. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $120.56.
Read Our Latest Stock Report on PRAX
About Praxis Precision Medicines
(
Get Free Report)
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Featured Articles
Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
